Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical and biotechnology company focused on developing effective, rapid-acting and convenient mental health treatments. The AtaiBeckley news feed on Stock Titan aggregates company announcements, press releases and regulatory disclosures so readers can follow how its clinical programs and corporate developments evolve over time.
News about AtaiBeckley frequently highlights progress across its pipeline of investigational therapies. This includes updates on BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray for treatment-resistant depression and alcohol use disorder; VLS-01, a DMT buccal film for treatment-resistant depression; and EMP-01, an oral R-MDMA formulation for social anxiety disorder. Company releases have covered Phase 2b and open-label extension data for BPL-003, enrollment and site expansion for VLS-01 trials, and exploratory Phase 2a work for EMP-01, as well as regulatory milestones such as FDA Breakthrough Therapy designation for BPL-003.
Investors and observers can also use the ATAI news page to follow corporate events, including the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited to form AtaiBeckley, the company’s redomiciliation to the United States as AtaiBeckley Inc., and its addition to the Nasdaq Biotechnology Index. Filings and press releases related to public offerings, grants from organizations such as the National Institute on Drug Abuse, and intellectual property developments like the U.S. patent granted for EMP-01 are also reflected in the news flow.
By reviewing AtaiBeckley news in one place, readers can track key clinical milestones, financing activities, regulatory designations and strategic transactions that shape the company’s efforts in mental health therapeutics. The ATAI news page can be revisited regularly to see new company communications and related market updates as they are released.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
atai Life Sciences (NASDAQ: ATAI) has initiated a Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine), with the first subject dosed. This open-label study aims to evaluate the safety, tolerability, and pharmacokinetic profiles of varying doses (60mg, 90mg, 120mg) administered subcutaneously compared to an intravenous dose. Approximately 16 healthy volunteers will be enrolled, with completion expected mid-2023. Earlier, atai reported Phase 2a results showing PCN-101's encouraging safety profile in treatment-resistant depression, although primary endpoints were not statistically significant. The current study could inform future dosing regimens for potential at-home use of R-ketamine as an antidepressant.
atai Life Sciences (NASDAQ: ATAI) reported its financial results for Q4 and full year 2022, highlighting progress in its clinical pipeline for mental health treatments. As of December 31, 2022, the company had $273 million in cash and equivalents, with access to an additional $160 million loan facility, ensuring funding into mid-2026. Key developments include the initiation of a Phase 2 study for RL-007 in cognitive impairment associated with schizophrenia and plans for Phase 2 studies of GRX-917 for anxiety. The net loss for 2022 decreased to $152.4 million from $167.8 million in 2021, indicating improved financial management.
atai Life Sciences (NASDAQ: ATAI) announced significant updates regarding its clinical pipeline and corporate strategy. The company has initiated a phase 2b study for RL-007, targeting cognitive impairment linked to schizophrenia, with initial results expected in late 2024. Additionally, atai plans to advance GRX-917 into a phase 2 study for anxiety disorders. The company has streamlined operations by reducing its workforce by approximately 30%, aiming to focus resources on key clinical developments. Importantly, the cash runway has been extended into the first half of 2026, indicating improved financial stability.